Introduction {#s1}
============

The adverse effect of tobacco use on health has been well established for over half a century. Consumption of tobacco is one of the leading causes of avoidable death globally. It is estimated that more than 8 million people may die from smoking and its related causes by 2030 [@pone.0047791-World1]. Metabolic syndrome includes the constellation of various metabolic abnormalities and confers an increased risk for diabetes and cardiovascular diseases. It is estimated that the prevalence of metabolic syndrome in adult was around 20-25% all over the world [@pone.0047791-International1].

The association of tobacco use with the onset of metabolic syndrome has been recognized in the past decade. Cigarette smoking has been proven to play a role in emergence of various components of metabolic syndrome and hence could lead to occurrence and progression of the disease through multiple mechanisms. However, available data from epidemiological studies on this issue are inconsistent and controversial. The positive correlation between smoking and metabolic syndrome is significant in some but not all studies [@pone.0047791-Balhara1], [@pone.0047791-Cena1]. One study conducted among Turkish women even found a protective effect of smoking on metabolic syndrome [@pone.0047791-Onat1]. Different definitions of metabolic syndrome and individual baseline information of the study population might lead to inconsistent results on this issue.

Previously existing literature and primary analyses on the association of smoking with the onset of metabolic syndrome did not complete a meta-analysis of data sources, and statistical power was inadequate and insufficient in these recent studies. As a result, the aim of the present meta-analysis is to assess the relationship between smoking and metabolic syndrome and to obtain a quantitative estimate of the risk.

Methods {#s2}
=======

Search strategy and study selection {#s2a}
-----------------------------------

We conducted a meta-analysis of the published works without language restrictions and in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [@pone.0047791-Stroup1]. We searched Medline, Embase, and the Cochrane Library from their inception to March 2012 and identified prospective studies that evaluated the effect of smoking on the risk of metabolic syndrome. The main search terms were "smoking" or "smoking cessation" or "tobacco" or "nicotine" or "cigarette" in combination with "metabolic syndrome" or "insulin resistance syndrome" or "syndrome X" with no restrictions. Reference lists from published original articles, and previous reviews were scanned for more relevant studies not identified in the databases search. Because of the high potential for intractable confounding and reverse causation, cross-sectional studies were excluded in this meta-analysis.

Studies were included in the meta-analysis if they met the following criteria: the study have a prospective cohort design; published quantitative estimates of the association between smoking and risk of metabolic syndrome in male or female; the endpoint of interest was incidence of metabolic syndrome; description of adjustment for potential confounders and had been adjusted at least for age [@pone.0047791-Huxley1]. Studies were excluded if the study selected a comparison group that was not nonsmokers; case-control design and cross-sectional design was used; study that examined other associations.

Data extraction and quality assessment {#s2b}
--------------------------------------

Two of our reviewers independently evaluated all relevant articles and identified eligible studies from the databases. During data abstraction, differences and disagreements were resolved through discussion to come to an agreement. We used standardized data extraction forms to record the following information: last name of the first author, publication year, geographic region of original study, mean length of follow-up, number of cases and participants, measurement of exposure and outcome, unadjusted and adjusted risk of developing metabolic syndrome for active smokers compared with nonsmokers with corresponding 95% confidence interval (CI) and adjustment factors of interest. Data for the association between former smoking and risk of metabolic syndrome was extracted when possible. In case of multiple publications from one study population, data relating to the most complete publication was extracted and included in the analysis. Researchers with professional knowledge in this area were queried for the presence of unpublished reports. We did not contact authors of the primary studies for additional information. As the data analyses were rely mainly on the published results, methodological quality was very important of the included studies. Hence, a 9-scores system on the basis of the Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included studies [@pone.0047791-GAWells1]. In this scoring system, each study included in the meta-analysis was judged on three broad perspectives: the selection of the study cases, the comparability of the study populations and the ascertainment of either the exposure or outcome of interest.

Statistical analysis {#s2c}
--------------------

Our primary analyses were focused on a comparison of the summary relative risk (RR) of metabolic syndrome in current smokers versus non-smokers. When studies presented results from various covariates analyses, we used the one adjusted for the main potential confounders, such as age, sex, body mass index (BMI), physical activity, alcohol consumption and weight change. The pooled estimates were calculated by averaging the natural logarithmic RR or hazard ratios or odds ratios (OR) weighted by their inverse of variance based on a fixed or random effects model within or between study variations, depending on the overall heterogeneity. Heterogeneity of effect size across studies was assessed by using Cochran\'s Q and the *I^2^* statistic [@pone.0047791-Higgins1], [@pone.0047791-Higgins2] and *P* value\<0.10 or *I^2^* value\>50% was considered to be heterogeneous. When substantial heterogeneity was detected, we calculated summary RR and their 95% CI with the method of DerSimonian and Laird in a random effects model [@pone.0047791-DerSimonian1]. If not, the pooled estimate was presented based on the fixed effects model by using the inverse variance method [@pone.0047791-Woolf1].

Nine studies defined a group of former smokers and therefore with a reference group defined as never smokers [@pone.0047791-Onat1], [@pone.0047791-Kim1], [@pone.0047791-Nakanishi1], [@pone.0047791-Zhu1], [@pone.0047791-Kim2], [@pone.0047791-Holme1], [@pone.0047791-Wannamethee1], [@pone.0047791-Kawada1], [@pone.0047791-Carnethon1], but 4 studies classified the exposure variable by smokers and nonsmokers [@pone.0047791-Yang1], [@pone.0047791-Wilsgaard1], [@pone.0047791-Li1], [@pone.0047791-Puustinen1], without information whether the nonsmoking group included former smokers. For this reason, we conducted a sensitivity analysis by including studies that used reference group as absolutely never smokers. Two long time duration follow-up studies (baseline survey in the 1970s) [@pone.0047791-Holme1], [@pone.0047791-Wannamethee1] could not screen metabolic syndrome (one excluded diabetes and the other excluded diabetes and coronary heart disease at the baseline survey) for lacking measurements of metabolic syndrome components. Hence, we conducted a sensitivity analysis by removing the 2 studies and recalculated the combined estimate on remaining studies. To assess the influence of individual studies on the pooled result, we conducted a sensitivity analysis by omitting one study in each turn.

Subgroup analyses according to gender (male/female), amount of smoking (heavy, ≥20 cigarettes per day/light, \<20 cigarettes per day), definition of metabolic syndrome (strict National Cholesterol Education Program \[NCEP\] III/other modified criteria compared with strict NCEP III definition), mean follow-up time (≥5 years/\<5 years), geographical area (Asia/Europe/North America), and study quality (high, NOS scores ≥7/low, NOS scores\<7) were used to assess the impacts of study characteristics on outcomes. Meta-regression analysis was used to investigate the influence of these variables on study heterogeneity across strata. We used the Begg\' s adjusted rank correlation test and the Egger\' s regression asymmetry test to detect publication bias and *P*\>0.05 for both tests was considered to be no significant publication bias. All statistical analyses were performed using STATA version 11.0 (Stata Corp, College Station, TX, USA).

Results {#s3}
=======

Literature search {#s3a}
-----------------

The details of the literature search were presented in a flow diagram ([Figure 1](#pone-0047791-g001){ref-type="fig"}). We identified 654 citations (137 from Medline, 479 from Embase and 38 from Cochrane Library) with our electronic literature search. We excluded 619 citations after screening based on abstracts or titles. After this, 35 remained citations and 2 retrieved citations were full-text reviewed. Finally, 13 citations met the inclusion criteria and were included in the meta-analysis.

![Flow diagram of study selection process.](pone.0047791.g001){#pone-0047791-g001}

Study characteristics and quality assessment {#s3b}
--------------------------------------------

The characteristics and information of the included studies were shown in [Table 1](#pone-0047791-t001){ref-type="table"}. The 13 selected studies contained 56,691 participants (ranging from 466 to 17,014) with 8,688 cases of metabolic syndrome from different populations (8 studies in Asia, 4 studies in Europe and 1 study in North America) and with varying length of the follow-up period (ranging from 1 to 28 years). Among the 13 included studies, 9 studies showed a significant positive correlation [@pone.0047791-Kim1], [@pone.0047791-Nakanishi1], [@pone.0047791-Zhu1], [@pone.0047791-Kim2], [@pone.0047791-Holme1], [@pone.0047791-Wannamethee1], [@pone.0047791-Kawada1], [@pone.0047791-Li1], [@pone.0047791-Puustinen1] and 1 study showed a significant inverse correlation between smoking and risk of metabolic syndrome [@pone.0047791-Onat1]. No significant positive association was found in the remaining 3 studies [@pone.0047791-Carnethon1], [@pone.0047791-Yang1], [@pone.0047791-Wilsgaard1]. Assessment of study specific quality scores from NOS system were summarized in [Table 2](#pone-0047791-t002){ref-type="table"}. The median score of included studies was 7, with a range from 5 to 9, and 76.9% of the studies were identified as relatively high-quality.

10.1371/journal.pone.0047791.t001

###### Characteristics of included studies of smoking and metabolic syndrome risk included in the meta-analysis.

![](pone.0047791.t001){#pone-0047791-t001-1}

                                                                                                                                                                Metabolic syndrome incidence by smoking status (No./Total)                        
  --------------------------------------------------- ------------------------------------ ------------ ------ --------------------------------- ------------- ------------------------------------------------------------ ---------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Kim 2009 Korea [@pone.0047791-Kim1]                              Male: 4542                   42       2.9            WHO Guidelines            482 (10.6)                             179/1292                             85/496    202/2528                            age, weight, lifestyle status, the number of metabolic syndrome components and weight change
  Yang 2008 Taiwan [@pone.0047791-Yang1]                All: 9785 Male:4707 Female:5078       19--84      4            Modified NCEP III          1245 (12.7)                               NA                                  NA         NA                                       age, education, alcohol consumption, occupational physical exertion and BMI
  Nakanishi 2005 Japan [@pone.0047791-Nakanishi1]                  Male: 2994               35--59 ^3^    7            Modified NCEP III          696 (21.9)                             353/1494                            143/585    160/915                                     age, family history of diabetes, alcohol consumption, and physical activity
  Zhu 2011 China [@pone.0047791-Zhu1]                              Male: 693                    57        3     Modified NCEP III ^4^ and JCDCG   150 (21.7)                              86/375                              23/95      41/222                                    age, education level, HOMA-IR, insulin, alcohol intake, BMI and weight change
  Kim 2007 Korea [@pone.0047791-Kim2]                              Male: 1578                 20--59      2                ACE/AACE               218 (13.8)                              NA/555                              NA/436     NA/405                                      age, waist hip rate, aminotransferase, low-density lipoprotein cholesterol
  Holme 2007 Norway [@pone.0047791-Holme1]                         Male: 6382               40--49 ^3^    28           Modified NCEP III          1597 (25.0)                            767/2801                            476/1979   354/1602                       age, years of education, glucose, triglycerides, BMI, treated hypertension and systolic blood pressure
  Wilsgaard 2007 Norway [@pone.0047791-Wilsgaard1]     All: 17014 Male: 8546 Female: 8468     20--61     13.8              NCEP III               1942 (11.4)                               NA                                  NA         NA                     age, time of baseline examination, alcohol intake, coffee consumption, years of education and physical activity
  Wannamethee 2006 UK [@pone.0047791-Wannamethee1]                 Male: 3051                 40--59      20               NCEP III               790 (25.6)                             119/405                             454/1686   228/952                             age, BMI, dietary fat, carbohydrate, physical activity, alcohol consumption and social class
  Onat 2006 Turkey [@pone.0047791-Onat1]                All: 1961 Male: 947 Female: 1014       ≥28       5.9           Modified NCEP III          472 (24.1)                                NA                                  NA         NA                                                   age, sex, physical activity grade and family income
  Kawada 2009 Japan [@pone.0047791-Kawada1]                        All: 2136                   45.4       1          Modified NCEP III ^5^         135 (6.3)                             NA/1006                                NA      NA/1070                                                            age, work history and HOMA-IR
  Li 2010 Japan [@pone.0047791-Li1]                                Male: 1897                 35-60       3                AHA/NHLBI               285 (15)                              125/660                              64/488     94/740                                       age, BMI, physical activity, healthy eating behaviors and weight change
  Puustinen 2011 Finland [@pone.0047791-Puustinen1]      All: 466 Male: 185 Female: 281         NA       6.4           Modified NCEP III           101 (22)                               NA/120                                NA         NA      age, sex, socioeconomic status, use of alcohol, leisure time physical activity, high sensitivity C-reactive protein and psychological distress
  Carnethon 2004 America [@pone.0047791-Carnethon1]    All: 4192 Male: 1869 Female: 2323       24.9      13.6              NCEP III               575 (13.7)                             NA/1203                              NA/553    NA/2436             age, race, sex, education, BMI, physical activity, alcohol consumption, energy intake, crude fiber intake and weight change

1\. WHO Guidelines, World Health Organization-West Pacific Region Guidelines; NCEP-ATP III, National Cholesterol Education Program\'s Adult Treatment Panel III; JCDCG, Chinese Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults definition; ACE/AACE, American College of Endocrinology/American Association of Clinical Endocrinologists criteria; AHA/NHLBI, American Heart Association/National Heart, Lung and Blood Institute criteria.

2\. BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance.

3\. Age of all participants (include those with metabolic syndrome at the baseline); NA, not recorded or available.

4\. We used the risk estimates from NCEP III definition in this study.

5\. Kawada used Japanese criteria which is similar to NCEP criteria except for lower waist circumference.

10.1371/journal.pone.0047791.t002

###### Assessment of Study Quality included in the meta-analysis. ^1^

![](pone.0047791.t002){#pone-0047791-t002-2}

                                                         Selection   Comparability ^2^   Outcome   Total Scores                        
  ----------------------------------------------------- ----------- ------------------- --------- -------------- --- --- --- ---- ---- ---
  Kim, 2009, Korea [@pone.0047791-Kim1]                      ☆               ☆             \-           ☆         ☆   ☆   ☆   \-   ☆    7
  Yang, 2008, Taiwan [@pone.0047791-Yang1]                   ☆               ☆             \-           ☆         ☆   ☆   ☆   \-   ☆    7
  Nakanishi, 2005, Japan [@pone.0047791-Nakanishi1]         \-               ☆              ☆           ☆         ☆   ☆   ☆   ☆    ☆    8
  Zhu, 2011, China [@pone.0047791-Zhu1]                      ☆               ☆              ☆           ☆         ☆   ☆   ☆   \-   \-   7
  Kim, 2007,Korea [@pone.0047791-Kim2]                      \-               ☆             \-           ☆         ☆   ☆   ☆   \-   ☆    6
  Holme, 2007, Norway [@pone.0047791-Holme1]                 ☆               ☆              ☆           \-        ☆   ☆   ☆   ☆    \-   7
  Wilsgaard, 2007, Norway [@pone.0047791-Wilsgaard1]         ☆               ☆             \-           ☆         ☆   ☆   ☆   ☆    ☆    8
  Wannamethee, 2006, UK [@pone.0047791-Wannamethee1]         ☆               ☆             \-           \-        ☆   ☆   ☆   ☆    ☆    7
  Onat, 2006, Turkey [@pone.0047791-Onat1]                   ☆               ☆             \-           ☆         ☆   ☆   ☆   ☆    ☆    8
  Kawada, 2009, Japan [@pone.0047791-Kawada1]               \-               ☆             \-           ☆         ☆   ☆   ☆   \-   ☆    6
  Li, 2010, Japan [@pone.0047791-Li1]                       \-               ☆             \-           ☆         ☆   ☆   ☆   \-   \-   5
  Puustinen, 2011, Finland [@pone.0047791-Puustinen1]        ☆               ☆              ☆           ☆         ☆   ☆   ☆   ☆    ☆    9
  Carnethon, 2004, America [@pone.0047791-Carnethon1]        ☆               ☆             \-           ☆         ☆   ☆   ☆   ☆    ☆    8

1\. Representativeness of the exposed cohort; 2.Selection of the non-exposed cohort; 3.Ascertainment of exposure; 4.Demonstration that outcome of interest was not present at start of study; 5.Comparability of cohorts on the basis of the design or analysis; 6.Assessment of outcome; 7.Was follow-up long enough for outcomes to occur; 8.Adequacy of follow up of cohorts.

2\. Studies that controlled for age received one score, whereas studies that controlled for other important confounders received an additional score.

3\. Study with follow-up time\>5 years was assigned one score.

4\. Study with follow-up rate\>75% was assigned one score.

Overall analyses {#s3c}
----------------

In overall analysis of the 13 selected studies, active smoking was associated with increased risk of metabolic syndrome ([Figure 2](#pone-0047791-g002){ref-type="fig"}, pooled RR 1.26, 95% CI: 1.10--1.44). Statistically significant evidence of heterogeneity was found across studies (*P*\<0.001, *I^2^* = 73.8%). There was no indication of publication bias either from the result of Egger\'s test (*P* = 0.227) or from the Begg\'s test (*P* = 0.113). We performed the pooled estimates in former male smokers as there was only one study with reported risk of metabolic syndrome for former female smokers (RR 0.94, 95% CI: 0.66--1.36) [@pone.0047791-Carnethon1]. Compared with nonsmokers, a borderline significant increased risk of metabolic syndrome was found in former male smokers ([Figure 3](#pone-0047791-g003){ref-type="fig"}, pooled RR 1.19, 95% CI: 1.00--1.42).

![Relative risks of metabolic syndrome for active smokers compared with nonsmokers.](pone.0047791.g002){#pone-0047791-g002}

![Relative risks of metabolic syndrome for former smokers compared with nonsmokers in male.](pone.0047791.g003){#pone-0047791-g003}

Subgroup analyses {#s3d}
-----------------

Subgroup analyses according to a number of characteristics to explore causes of the study heterogeneity were shown in [Table 3](#pone-0047791-t003){ref-type="table"}. The result of increased metabolic syndrome risk in active smokers was consistently found in the stratified analyses except when stratified by gender. Male smokers (pooled RR 1.34, 95% CI: 1.20--1.50) seemed to have a substantially greater metabolic syndrome risk as compared with female smokers (pooled RR 0.85, 95% CI: 0.60--1.21).Moreover, the difference was statistically significant in meta-regression analysis (*P* = 0.02). In the dose-response analysis, compared with light smokers (pooled RR 1.10, 95% CI: 0.90--1.35), the risk of metabolic syndrome was stronger and more significant in heavy smokers (pooled RR 1.42, 95% CI: 1.27--1.59). As shown in [Table 3](#pone-0047791-t003){ref-type="table"}, modified definitions of metabolic syndrome appear to have some influence on the consequences, however, definition by strict NCEP III (pooled RR 1.11, 95% CI: 1.02--1.21) and all other definitions (pooled RR 1.32, 95% CI: 1.09--1.60) reported a significant association between smoking and risk of metabolic syndrome. In the stratified analysis by mean follow-up time, the positive association between smoking and metabolic syndrome was slightly weaker if follow-up duration more than 5 years (pooled RR 1.16, 95% CI: 0.99--1.35). In a study carried out in North America, no significant evidence of association between smoking and risk of metabolic syndrome was found (RR 1.18, 95% CI: 0.97--1.44). However, such correlation was significant in studies performed in Asia (pooled RR 1.29, 95% CI: 1.01--1.64) and Europe (pooled RR 1.21, 95% CI: 1.04--1.41). When stratified by study quality according to NOS scoring system, both high quality studies (pooled RR 1.20, 95% CI: 1.04--1.38) and low quality studies (pooled RR 1.58, 95% CI: 1.29--1.95) showed consistent positive association between smoking and risk of metabolic syndrome.

10.1371/journal.pone.0047791.t003

###### Stratified Analyses of Pooled Relative Risks of Metabolic Syndrome for Smoker.
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  Group                                NO. of studies      RR (95% CI)      *P* ~for\ heterogeneity~   *I* ^2^ (%)   *P* ~for\ meta-regression~
  ----------------------------------- ---------------- ------------------- -------------------------- ------------- ----------------------------
  Gender                                                                                                                        0.02
  Male                                       10         1.34 (1.20--1.50)             0.02                54.9      
  Female                                     4          0.85 (0.60--1.21)             0.02                71.2      
  Amount of smoking                                                                                                             0.07
  Heavy (≥20 cigarettes/d)                   3          1.42 (1.27--1.59)             0.02                68.9      
  Light (\<20 cigarettes/d)                  3          1.10 (0.90--1.35)             0.31                16.5      
  Definitions of metabolic syndrome                                                                                             0.45
  Strict NCEP III                            3          1.11 (1.02--1.21)             0.44                0.00      
  Other                                      10         1.32 (1.09--1.60)             0.00                78.1      
  1 risk factor modified^\*^                 4          1.37 (1.22--1.55)             0.49                0.00      
  2 risk factors modified                    4          1.36 (1.00--1.84)             0.02                65.5      
  \>2 risk factors modified                  2          1.04 (0.48--2.25)             0.00                95.5      
  Mean follow-up time                                                                                                           0.18
  ≥5 years                                   7          1.16 (0.99--1.35)             0.00                76.8      
  \<5 years                                  6          1.44 (1.18--1.75)             0.05                52.1      
  Geographical area                                                                                                             0.77
  Asia                                       8          1.29 (1.01--1.64)             0.00                81.6      
  Europe                                     4          1.21 (1.04--1.41)             0.07                53.9      
  North America                              1          1.18 (0.97--1.44)              \-                  \-       
  Study quality                                                                                                                 0.17
  High (NOS scores≥7)                        10         1.20 (1.04--1.38)             0.00                75.8      
  Low (NOS scores\<7)                        3          1.58 (1.29--1.95)             0.97                0.00      

Modified criteria used to diagnose metabolic syndrome as compared with strict NCEP III definition.

Sensitivity analyses {#s3e}
--------------------

A sensitivity analysis was carried out by including 9 studies in which the comparison with a reference group defined as strictly never smokers (no former smokers) and the pooled RR was 1.32 (95% CI: 1.10--1.59). By removing the 2 studies which could not biologically screen metabolic syndrome at the baseline, the combined results showed that positive relation between smoking and risk of metabolic syndrome continued to be significant 1.25 (95% CI: 1.07--1.46). Similarly, we investigated the influence of a single study on the overall risk estimate by excluding one study at a time. The combined RR of overall risk estimates were consistent and without apparent fluctuation, with a range from 1.23 (95% CI: 1.08--1.40) to 1.31 (95% CI: 1.18--1.46). Moreover, studies used RR or OR to calculate the association showed a coincident outcome, with a pooled value of 1.13 (95% CI: 1.04--1.22) and 1.41 (95% CI: 1.13--1.77), respectively.

Discussion {#s4}
==========

Findings of the present meta-analysis show a clear link between smoking and risk of metabolic syndrome. Based on data from 13 prospective cohort studies (56,691 participants; 8,688 incident cases of metabolic syndrome), active smokers have a 26% increased risk of metabolic syndrome compared with nonsmoking individuals. The combined estimate of our primary analysis was strong across multiple sensitivity analyses and without significant publication bias.

A previous study has shown the risk for the development of metabolic syndrome was significantly lower in female heavy smokers [@pone.0047791-Onat1]. However, when reporting a beneficial effect of such a harmful exposure as smoking, we cannot be too cautious to draw a conclusion. In the current analysis, our results showed no sign of significance protective effect of smoking on metabolic syndrome in female. Even though, the present analyses might still have underestimated the true risk of metabolic syndrome in female smokers. At first, it will take time to observe the full effect of smoking on metabolic syndrome risk in female. On one hand, both the proportion of heavy smokers and the mean daily consumption of cigarettes are generally lower in female smokers [@pone.0047791-Woodward1]. On the other hand, as compared to male smokers, female smokers are usually younger and not so common, at least in some areas of the world [@pone.0047791-Martiniuk1]. Moreover, more female smokers than male conceal their smoking habit which will give rise to the misclassification of the smoking exposure and attenuation of metabolic syndrome risk of the present analyses [@pone.0047791-Huxley1], [@pone.0047791-Strauss1].

A clear interaction between susceptibility and dose admits of a simple explanation in establishing causation of any environmental factor [@pone.0047791-Hill1]. In the present meta-analysis, we found a dose-response relationship between smoking and risk of metabolic syndrome, with stronger correlation for heavy smokers than light smokers. The gathering of other risk factors in heavy smokers and the incomprehensive data recording of included studies can cause such relationship. In addition, the most effective therapeutic way for smokers to attenuate the adverse effects of metabolic disorders and cardiovascular disease is to stop smoking. This is consistent with our finding that risk of metabolic syndrome in male was stronger for current smokers than it was for former smokers. Reduction of the triglyceride and improved insulin sensitivity and high density lipoprotein may adequate to account for the benefit of stop smoking [@pone.0047791-He1]. Although somewhat arbitrary, we preliminarily inferred that smoking cessation may help to reduce the incidence of metabolic syndrome, at least for male smokers. Nevertheless, association between smoking and metabolic syndrome was less strong in studies with follow-up more than 5 years. This is probably because 2 [@pone.0047791-Holme1], [@pone.0047791-Wannamethee1] of the 7 studies in this subgroup could not biologically exclude metabolic syndrome in their 1970s baseline survey. However, in order to obtain a long-range and more comprehensive assessment of the association between smoking and metabolic syndrome, our primary analysis was carried out by including those studies. Further sensitive analysis by removing the 2 studies showed that the association is still positive and significant.

It is biologically plausible that smoking could increase the risk of metabolic syndrome. Exposure to tobacco has been found to play a core role in emergence of many metabolic disorders. Certain evidences exist that smoking can increase blood pressure, waist circumference, triglycerides, and reduce high density lipoprotein cholesterol. Moreover, compared with nonsmokers, active smokers usually have more serious insulin resistance and hyperinsulinemia, which may increase the risk of type 2 diabetes [@pone.0047791-Willi1]. The effect of cigarette smoking on glucose and lipid metabolism may partly attribute to stimulation of sympathetic nervous system [@pone.0047791-Williamson1] and increase of circulating insulin-antagonistic hormones levels, such as cortisol and growth hormone [@pone.0047791-Wilkins1]. Elevated plasma cortisol concentration and aggravated insulin resistance can cause localization of visceral fat mass and increase of waist circumference. In addition to the hormone disturbance, several lines of evidence have shown that endothelial dysfunction and its related arterial compliance reduction were more serious in smokers, which may have significant influence on insulin resistance and compensatory hyperinsulinemia [@pone.0047791-Winkelmann1], and hence could contribute to development and deterioration of metabolic syndrome [@pone.0047791-Bigazzi1]. Although smoking is known to be associated with weight loss in several studies [@pone.0047791-Albanes1], [@pone.0047791-Gordon1], clear evidence exist that smokers (especially heavy smokers) have higher BMI [@pone.0047791-Chiolero1] and greater risk of abdominal fat accumulation than nonsmokers [@pone.0047791-Shimokata1].

There were several limitations to this meta-analysis. First, the distinct definition of metabolic syndrome might provide biased estimates on the risk of the disease attributed to smoking. The concept of metabolic syndrome has existed for at least ten decades and a variety of definitions have been prescribed by organizations including the NCEP expert panel, American College of Endocrinology (ACE), American Heart Association (AHA), and the World Health Organization (WHO). Among these definitions, the Third Report of the NCEP\' s Adult Treatment Panel (NCEP III) in the year 2001 provided a relatively simple and feasible approach for detecting components of metabolic syndrome, which make the definition widely used in both clinical and epidemiological studies. Actually, in the effort to early recognize high-risk groups and emphasize ethnic differences, criteria were modified with the attempt to best estimates for the hazards of metabolic syndrome. For example, studies carried out in Asia usually revised waist circumference to obtain a threshold more appropriate for Asian populations [@pone.0047791-Gu1]. In the current analysis, metabolic syndrome was defined by rigorous NCEP III and modified NCEP III criteria in most of the included studies. Pooled RR of the metabolic syndrome were statistical significant in studies using strict NCEP III and other definitions.

Another limitation was the incomprehensive coverage of information of the present analysis. After all, the results in this analysis were only obtained data from Asia, Europe and North America and the majority of the included studies did not state if there were any racial differences among participants. The distinctions in regions and races among studies might have an influence on pooled risk estimates of metabolic syndrome. Nevertheless, stratified analysis showed that participants from both Asia and Europe had significant risk estimates. Moreover, in the present analysis of 13 studies, 10 studies were specific for cigarette smoking, while estimation of smoking from other tobacco products (cigars or pipes) were not clear in the rest 3 studies. Actually, no studies have investigated the effect of different types of smoking on the risk of metabolic syndrome and we cannot estimate whether such types of smoking are equivalent in their effects.

Third, evidence suggests that risk of metabolic syndrome could be biased by methodological features of the included studies. As the data on smoking status was based on self-declaration, risk of metabolic syndrome may be underestimated if participants did not reasonably reported the habits of cigarette smoking when completing questionnaires. However, studies have shown that the reliability of self-reported smoking habits is robust and highly correlated with exhaled carbon monoxide values [@pone.0047791-Frei1]. In addition, the discordance between studies in definition of non-smokers may lead to selection bias. Some studies clearly defined non-smokers as people who had never smoked whereas others just dichotomized the exposure variable as smokers and non-smokers. We speculated that former smokers and never smoker were combined into one category as non-smoker in these studies. This form of classification will conceal the hazards of smoking and limit information about risk analyses for the two groups separately. Nevertheless, sensitivity analysis suggested that the results were stable in different definition of non-smokers.

Finally, substantial heterogeneity, partly due to diversity in gender and dose of exposure, was noted in current analysis. Such heterogeneity was not surprising because of unavoidable variations in study population and distinct adjustments across studies. Strong clustering of unhealthy lifestyles, such as little exercise, excessive drinking and poor diet, were more common in people smoking than in the general population. Not all of these factors were adjusted and taken into account in the studies included in our meta-analysis, which could contribute to a superficially robust association between smoking and metabolic syndrome. Nevertheless, all included studies have adjusted for age and most of them have adjusted for a wide range of potential confounders (9 of the 13 studies adjusted ≥5 confounders).

In conclusion, findings of the present meta-analysis of prospective cohort studies suggest that active smoking is associated with higher risk of metabolic syndrome. The conclusion has a far-reaching significance for public health, especially in countries of high smoking prevalence and high incidence of metabolic syndrome. Further investigations, both epidemiological and mechanistic, are needed to establish the extent to which the association can be explained by a causal link and whether smoking cessation can prevent occurrence and development of metabolic syndrome.
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